Upgrade to SI Premium - Free Trial

Verastem Oncology (VSTM)

4.01 +0.01 (0.25%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

VERASTEM doses first patient in Phase 2 pancreatic cancer trial June 16, 2026 4:01 PM - StreetInsider Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer June 16, 2026 4:01 PM - BizWire Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program June 15, 2026 4:01 PM - BizWire Buy this biotech stock now, Mizuho urges June 9, 2026 2:00 PM - StreetInsider FDA grants fast track status to Verastem's lung cancer drug VS-7375 June 3, 2026 4:01 PM - StreetInsider Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally June 3, 2026 4:01 PM - BizWire Form S-8 Verastem, Inc. May 29, 2026 4:41 PM - SEC Filing Form 4 Verastem, Inc. For: May 21 Filed by: BAILEY MICHAEL P May 27, 2026 5:46 PM - SEC Filing Form 3 Verastem, Inc. For: May 21 Filed by: BAILEY MICHAEL P May 27, 2026 5:44 PM - SEC Filing Form 144 Verastem, Inc. Filed by: Gagnon Robert E. May 27, 2026 4:48 PM - SEC Filing Verastem Oncology to Present at Jefferies Healthcare Conference May 27, 2026 7:30 AM - BizWire Form 4 Verastem, Inc. For: May 21 Filed by: Tollefson Karin Anna May 26, 2026 6:24 PM - SEC Filing Form 4 Verastem, Inc. For: May 21 Filed by: Stuglik Brian M May 26, 2026 6:22 PM - SEC Filing Form 4 Verastem, Inc. For: May 21 Filed by: Rowinsky Eric K May 26, 2026 6:21 PM - SEC Filing Form 4 Verastem, Inc. For: May 21 Filed by: ROBERTSON MICHELLE May 26, 2026 6:20 PM - SEC Filing Form 4 Verastem, Inc. For: May 21 Filed by: Kapur Anil May 26, 2026 6:18 PM - SEC Filing Form 4 Verastem, Inc. For: May 21 Filed by: Bunn Paul A. May 26, 2026 6:13 PM - SEC Filing Form 4 Verastem, Inc. For: May 21 Filed by: JOHNSON JOHN May 26, 2026 6:12 PM - SEC Filing Form 8-K Verastem, Inc. For: May 21 May 26, 2026 8:15 AM - SEC Filing Verastem Oncology appoints Michael Bailey to board of directors May 26, 2026 7:30 AM - StreetInsider Verastem Oncology Appoints Michael P. Bailey to its Board of Directors May 26, 2026 7:30 AM - BizWire Form SCHEDULE 13G/A Verastem, Inc. Filed by: Foresite Capital Fund VI LP May 15, 2026 4:30 PM - SEC Filing Form SCHEDULE 13G/A Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC May 15, 2026 11:08 AM - SEC Filing Form SCHEDULE 13G/A Verastem, Inc. Filed by: RTW INVESTMENTS, LP May 15, 2026 8:43 AM - SEC Filing Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P. May 15, 2026 6:36 AM - SEC Filing Verastem (VSTM) PT Lowered to $14 at Mizuho May 14, 2026 6:38 AM - StreetInsider Verastem Oncology to Present at Upcoming Investor Conferences May 12, 2026 7:30 AM - BizWire On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer May 8, 2026 7:30 AM - BizWire Verastem (VSTM) PT Lowered to $18 at BTIG May 8, 2026 6:56 AM - StreetInsider Verastem Oncology (VSTM) Misses Q1 EPS by 43c May 7, 2026 4:24 PM - StreetInsider Form 8-K Verastem, Inc. For: May 07 May 7, 2026 4:14 PM - SEC Filing Form 10-Q Verastem, Inc. For: Mar 31 May 7, 2026 4:09 PM - SEC Filing Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates May 7, 2026 4:01 PM - BizWire Form 4 Verastem, Inc. For: May 04 Filed by: Paterson Dan May 6, 2026 4:01 PM - SEC Filing Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer April 30, 2026 7:30 AM - BizWire Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 April 23, 2026 7:30 AM - BizWire H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM) April 13, 2026 6:41 AM - StreetInsider BTIG on Verastem (VSTM): data supports drug's ~$1B peak sales potential April 10, 2026 12:26 PM - StreetInsider Verastem presents two-year follow-up data for ovarian cancer therapy April 10, 2026 7:00 AM - StreetInsider Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the S April 10, 2026 7:00 AM - BizWire Form DEF 14A Verastem, Inc. For: May 21 April 9, 2026 4:16 PM - SEC Filing Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 2, 2026 4:05 PM - BizWire Verastem (VSTM) PT Lowered to $15 at Jefferies March 27, 2026 4:17 PM - StreetInsider Form SCHEDULE 13G/A Verastem, Inc. Filed by: VANGUARD GROUP INC March 27, 2026 1:52 PM - SEC Filing Form 4 Verastem, Inc. For: Mar 20 Filed by: Calkins Daniel March 23, 2026 5:20 PM - SEC Filing Full Article List